JP2019535737A - 低用量チオグアニンによるインビボ化学選択 - Google Patents

低用量チオグアニンによるインビボ化学選択 Download PDF

Info

Publication number
JP2019535737A
JP2019535737A JP2019527238A JP2019527238A JP2019535737A JP 2019535737 A JP2019535737 A JP 2019535737A JP 2019527238 A JP2019527238 A JP 2019527238A JP 2019527238 A JP2019527238 A JP 2019527238A JP 2019535737 A JP2019535737 A JP 2019535737A
Authority
JP
Japan
Prior art keywords
amount
administered
day
weeks
doses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019527238A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535737A5 (enExample
Inventor
ジェフリー エス． バートレット
ジェフリー エス． バートレット
ルイス ランダル ブレトン
ルイス ランダル ブレトン
Original Assignee
カリミューン， インコーポレーティッド
カリミューン， インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カリミューン， インコーポレーティッド, カリミューン， インコーポレーティッド filed Critical カリミューン， インコーポレーティッド
Publication of JP2019535737A publication Critical patent/JP2019535737A/ja
Publication of JP2019535737A5 publication Critical patent/JP2019535737A5/ja
Priority to JP2022192549A priority Critical patent/JP2023025149A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2019527238A 2016-11-18 2017-11-17 低用量チオグアニンによるインビボ化学選択 Pending JP2019535737A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022192549A JP2023025149A (ja) 2016-11-18 2022-12-01 低用量チオグアニンによるインビボ化学選択

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423794P 2016-11-18 2016-11-18
US62/423,794 2016-11-18
PCT/US2017/062127 WO2018094126A1 (en) 2016-11-18 2017-11-17 In vivo chemoselection with low dose thioguanine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022192549A Division JP2023025149A (ja) 2016-11-18 2022-12-01 低用量チオグアニンによるインビボ化学選択

Publications (2)

Publication Number Publication Date
JP2019535737A true JP2019535737A (ja) 2019-12-12
JP2019535737A5 JP2019535737A5 (enExample) 2020-12-24

Family

ID=60915599

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019527238A Pending JP2019535737A (ja) 2016-11-18 2017-11-17 低用量チオグアニンによるインビボ化学選択
JP2022192549A Pending JP2023025149A (ja) 2016-11-18 2022-12-01 低用量チオグアニンによるインビボ化学選択

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022192549A Pending JP2023025149A (ja) 2016-11-18 2022-12-01 低用量チオグアニンによるインビボ化学選択

Country Status (8)

Country Link
US (2) US20180140606A1 (enExample)
EP (1) EP3541392A1 (enExample)
JP (2) JP2019535737A (enExample)
KR (1) KR20190086497A (enExample)
CN (1) CN109963566A (enExample)
AU (1) AU2017363154A1 (enExample)
CA (1) CA3041531A1 (enExample)
WO (1) WO2018094126A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4190339B1 (en) * 2017-07-18 2025-07-02 CSL Behring Gene Therapy, Inc. A modulatable switch for selection of donor modified cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014512391A (ja) * 2011-04-20 2014-05-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 単一サイクルでコンディショニングおよび化学選択を組み合わせる方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014512391A (ja) * 2011-04-20 2014-05-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 単一サイクルでコンディショニングおよび化学選択を組み合わせる方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
「新医薬品の臨床評価に関する一般指針について」（薬新薬第四三号）各都道府県衛生主管部局長あて厚生省薬, JPN6021034322, 1992, pages 1 - 12, ISSN: 0004838379 *
BLOOD, vol. 112, no. 12, JPN6021036662, 2008, pages 4466 - 4474, ISSN: 0004597370 *
EXPERIMENTAL HEMATOLOGY, vol. 40, JPN6021036661, 2012, pages 3 - 13, ISSN: 0004838377 *
GUIDANCE FOR INDUSTRY, ESTIMATING THE MAXIMUM SAFE STARTING DOSE IN INITIAL CLINICAL TRIALS FOR THER, JPN6021034319, 2005, pages 1 - 27, ISSN: 0004838378 *

Also Published As

Publication number Publication date
WO2018094126A1 (en) 2018-05-24
KR20190086497A (ko) 2019-07-22
AU2017363154A9 (en) 2019-07-11
AU2017363154A1 (en) 2019-05-16
EP3541392A1 (en) 2019-09-25
CN109963566A (zh) 2019-07-02
JP2023025149A (ja) 2023-02-21
US20180140606A1 (en) 2018-05-24
US20190269687A1 (en) 2019-09-05
CA3041531A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
JP7155206B2 (ja) 神経学的疾患または障害を処置するためのｖｍａｔ２阻害剤
ES2717279T3 (es) Baricitinib deuterada
TWI674897B (zh) 藉二氫吡并吡化合物組合療法的癌症治療方法
JP2004531523A (ja) アデノシンａ３レセプターアゴニストによるナチュラルキラー細胞の活性化
JP5890043B2 (ja) 抗癌活性を有する２−デオキシ単糖の新規なアセテート
KR20180039164A (ko) 세포 내 atp 증강제
Kukhanova Anti-HIV nucleoside drugs: A retrospective view into the future
US11998551B2 (en) Treatment of mitochondrial diseases
JP2025061603A (ja) 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用
JP2023025149A (ja) 低用量チオグアニンによるインビボ化学選択
JP2004527460A (ja) 上昇したプリンレベルを有している患者のためのウリジン療法
WO2009109356A1 (en) Cytostatic compositions
CA2672716C (fr) Nouvelle utilisation therapeutique pour le traitement des leucemies
Ullman Pyrazolopyrimidine metabolism in parasitic protozoa
HK40003311A (en) In vivo chemoselection with low dose thioguanine
Leung Iatrogenic mitochondriopathies: a recent lesson from nucleoside/nucleotide reverse transcriptase inhibitors
Roberts et al. Effect of methotrexate and 1-β-D-arabinofuranosylcytosine on pools of deoxyribonucleoside triphosphates in L1210 ascites cells
US20240091247A1 (en) Inhibitor for chronic myeloid leukemia stem cells
WO1993018776A1 (en) Combinations of compounds having antiviral activity
Lamanna et al. Purine analogs in leukemia
JP2019535737A5 (enExample)
Curbo et al. 9-β-D-Arabinofuranosylguanine
Kaplinsky et al. Purine metabolism in human neuroblastoma cell lines
BR112017027839B1 (pt) Uso de inibidores de vmat2 para preparação de uma composição farmacêutica para tratar mania em um transtorno de humor em um indivíduo; e/ou tratar transtorno obsessivo-compulsivo (toc) refratário ao tratamento
MXPA99010735A (en) THE USE OF 1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES FOR THE PREPARATION OF MEDICAMENTS USEFUL FOR THE TREATMENT OF CEREBROVASCULAR DISTURBANCES

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201113

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210420

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210922

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220322

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220801